Julie Grisham, MS

Researchers have produced a fully synthetic, functional version of erythropoietin, the hormone that controls production of red blood cells.

Dr. Rudensky studies the development of white blood cells called T lymphocytes, which participate in the immune system response to infection. He joined the Sloan-Kettering Institute in 2009.

Eric Holland, Director of the Brain Tumor Center, is a neurosurgeon and researcher who studies the molecular changes that occur in glioblastoma and other brain tumors.

Memorial Sloan-Kettering’s trial to evaluate a new therapy for patients with beta-thalassemia is the first to receive FDA approval to treat this disease with genetically engineered cells.

Researchers have demonstrated a technique that enables specific and accurate labeling of brain tumor tissue in mice. If proven effective in patients, the method could make complete surgical removal of brain tumors more feasible.

Two Memorial Sloan-Kettering studies provide new clues about genetic mutations that affect cell behavior and play a role in several types of cancer.

Infections are a common cause of complications in cancer patients. Now a Memorial Sloan-Kettering research team finds that a commonly prescribed antibiotic could increase susceptibility to a bacterial infection.